ADDvise acquires CliniChain Holding B.V.

06-12-2022   Regulatory press release

ADDvise Group AB has today entered into a share purchase agreement with the owners of CliniChain Holding B.V. (“CliniChain”) regarding the acquisition of all the outstanding shares of CliniChain in accordance with the letter of intent communicated via a press release dated September 6, 2022. Closing of the acquisition takes place no later than December 16, 2022.

CliniChain wins order worth EUR 12.8 million

CliniChain’s revenue for the last twelve months per October 31, 2022 amounted to approximately EUR 7.4 million, with an adjusted EBITDA of approximately EUR 4.0 million, corresponding to an adjusted EBITDA margin of approximately 53.7 percent. Approximately 60 percent of CliniChain’s revenue is recurring revenue. Thereafter CliniChain signed an agreement with one of the world's largest contract research organizations ("CRO") that will perform a global risk study on behalf of one of their customers. The agreement concerns rental, training and service of medical equipment. The contract runs for 33 months starting immediately and has a total order value of approximately EUR 12.8 million. The agreement will significantly increase CliniChain's turnover and result over the next three years.

Transaction structure

The purchase price amounts to a total of EUR 33.8 million. The initial purchase price amounts to EUR 25.9 million, divided between a cash payment of EUR 20.0 million and a two-year promissory note of EUR 5.9 million. The promissory note carries an annual interest rate of 1.0 percent. Furthermore, two potential earn-outs can be paid out for a total of EUR 7.9 million, given that CliniChain achieves certain predetermined targets based on materially higher financial targets than the company's performance for the last twelve months.

The acquisition is financed through own funds and loan through additional senior secured bonds as previously communicated. ADDvise assesses that the acquisition will have a positive impact on ADDvise’s earnings per share during the financial year 2023.


Mangold Fondkommission AB is the financial adviser to ADDvise for the acquisition.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 6 December 2022 at 15:25 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB is the Company's Certified Adviser. Additional information is available at

Latest press releases

ADDvise acquires Axelerist, Inc.


ADDvise Group has entered into a share purchase agreement with the owner of Axelerist, Inc. (“Axelerist”) regarding the acquisition of all shares of Axelerist. Closing of the acquisition takes place today. Axelerist, based in Yorktown Heights, New York, is a leading provider of tailored rental and purchase solutions of MedTech- and laboratory equipment for clinical…

ADDvise Group successfully issues subsequent senior secured bonds of SEK 450 million


ADDvise Group AB (publ) has successfully issued subsequent senior secured bonds of SEK 450 million under its existing bond loan with ISIN SE0020180271. Following the bond issue, in total SEK 1,450 million will be outstanding under the framework. The subsequent bonds was priced at 101.75% of par and carry a floating interest rate of STIBOR…

ADDvise Group contemplates issuance of subsequent bonds of SEK 400 million


ADDvise Group AB (publ) has mandated Pareto Securities AB and Skandinaviska Enskilda Banken AB (publ) to arrange a series of credit investor meetings commencing on 30 October 2023. A subsequent issue of senior secured bonds in an expected amount of SEK 400 million under the company's existing senior secured bond loan with a framework of…

ADDvise Group’s nomination committee for the Annual General Meeting 2024


In accordance with the resolution at the Annual General Meeting 2022 of ADDvise Group, the nomination committee for the Annual General Meeting 2024 shall comprise of representatives of the three largest shareholders by votes, according to the shareholders’ register as of 30 June 2023 maintained by Euroclear Sweden, and of the chairman of the board…